Clinical Trial Update: A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Bacillus Calmette-Guérin in adults with mild cognitive impairment and Alzheimer's disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• BCG vaccine (Bacillus Calmette-Guérin)

Snippet

Sponsor: Steven E Arnold, MD | Conditions: Mild Cognitive Impairment, Mild Dementia | Phase 2 | Status: COMPLETED | Results posted: 2025-04-13